<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053219</url>
  </required_header>
  <id_info>
    <org_study_id>AC201606AVTN07</org_study_id>
    <nct_id>NCT03053219</nct_id>
  </id_info>
  <brief_title>Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment</brief_title>
  <official_title>An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou ACEA Pharmaceutical Research Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hangzhou ACEA Pharmaceutical Research Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced
      NSCLC who participant in [14C] AC0010 ADME.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced
      NSCLC who participant in [14C] AC0010 ADME (absorption, distribution, metabolism and
      excretion) trial and subsequent receiving AC0010 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months</time_frame>
    <description>To assess the overall Objective Response Rate(ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months</time_frame>
    <description>To assess the Progression Free Survival(PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months</time_frame>
    <description>To assess the Disease control rate(DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AE) experienced by patients to assess safety</measure>
    <time_frame>From date of Signed informed consent forms until 30 days after disease progression, intolerable toxicity or withdrawal from study, approximately up to 18 months)</time_frame>
    <description>To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Carcinoma，Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>AC0010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each participant will be given AC0010 300mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC0010</intervention_name>
    <description>Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours</description>
    <arm_group_label>AC0010</arm_group_label>
    <other_name>AC0010MA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  histologically or cytologically confirmed diagnosis of local advanced or recurrent
             NSCLC

          -  failed to the treatment of EGFR-TKI and harbored T790M mutation

          -  male, Age 18~ 65, have a body mass index (BMI)&gt;19 kg/m2

          -  Eastern Cooperative Oncology Group performance status(ECOG PS):0-1,Life expectancy of
             more than 3 months

          -  main organs function is normal, laboratory values as listed below: blood test without
             blood transfusion within 14 days

               1. Haemoglobin &gt;100 g/L

               2. Absolute neutrophil count ≥2.0x10^9/L or WBC ≥3.5 x10^9/L

               3. Platelet count ≥ 80x10^9/L

               4. Total bilirubin ≤1.5xULN

               5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times
                  upper limit of normal (ULN)

               6. Serum creatinine ≤1.5xULN or creatinine clearance ratio ≥60 mL/ min

          -  Any prior treatment (chemotherapy, radiotherapy or surgery) must be completed over 4
             weeks(target therapy over 2 weeks) from the screening; Patients must have recovered
             from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03)

          -  International normalized ratio (INR) ≤ 1.5

          -  Patients and their partners should be willing to use methods of contraception or total
             abstinence from start of dosing until 6 months after discontinuing of study treatment

          -  Patients must withdraw from previous study of [14C] AC0010

        Exclusion Criteria:

          -  Prior treated with AC0010 or allergic to drug or its formulation ingredients

          -  Patients receiving other anti-tumor therapy

          -  Impairment of GI disease, renal disorders or liver disease that may significantly
             alter the absorption and metabolic of AC0010 (e.g., Unable to swallow, liver, kidney
             or gastrointestinal partial resection, chronic diarrhea and intestinal obstruction)

          -  HCVAb positive, active hepatitis B (excluding HBV carriers), Hepatitis virus markers
             positive and receiving anti-virus drugs

          -  Meningeal metastasis; brain metastasis with whole brain radiotherapy; prior received
             hormones or mannitol for the brain metastasis

          -  Previous EGFR-TKI treatment related Interstitial lung disease history

          -  Known human immunodeficiency virus infection (HIV), other acquired or congenital
             immunodeficiency disease, or a history of organ transplantation

          -  Any severe and / or uncontrolled active infections

          -  Patients receiving concomitant immunosuppressive agents or high-dose corticosteroids

          -  Any severe and / or uncontrolled medical conditions

          -  Patients being treated with drugs recognized as being inhibitors or inducers of the
             liver isoenzyme in the last 4 weeks prior to registration in the current study

          -  Within 3 days prior to the treatment taking of dragon fruit, pomelo, grapefruit,
             orange, mango and other fruit may affect drug metabolizing enzymes or juice

          -  Major surgery, incisional biopsy or traumatic injuries;

          -  Within 4 weeks prior to the screening patients with bleeding ≥ grade 3, non-healing
             wound, sever ulcer or bone fracture

          -  Patients received high dose irradiation treatment or other 14C-labeled drug within 1
             year

          -  Known a history of alcoholism or drug abuse

          -  Investigator judgment that patient is unsuitable to participate in study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lingxiang Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanhong Xu, PhD</last_name>
    <phone>+86 571 28909102</phone>
    <email>kayla.liu@aceabio.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renhua Guo, Doctor</last_name>
      <email>guorenhua@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Renhua Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

